Skip to main content
NCBI home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(6):557–563. doi: 10.1111/j.1349-7006.2003.tb01482.x

Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells

Motoi Mukai 1,2,5, Xiao‐Fang Che 1,5, Tatsuhiko Furukawa 1, Tomoyuki Sumizawa 1, Shunji Aoki 3, Xiao‐Qin Ren 1, Misako Haraguchi 1, Yoshikazu Sugimoto 4, Motomasa Kobayashi 3, Hideo Takamatsu 2, Shin‐ichi Akiyama 1,✉
PMCID: PMC11160154  PMID: 12824882

Abstract

STI571, an Abl‐specific tyrosine kinase inhibitor, selectively kills Bcr‐Abl‐containing cells in vitro and in vivo. However, some chronic myelogenous leukemia (CML) cell lines are resistant to STI571. We evaluated whether STI571 interacts with P‐glycopro‐tein (P‐gp) and multidrug resistance protein 1 (MRP1), and examined the effect of agents that reverse multidrug resistance (MDR) on the resistance to SI571 in MDR cells. STI571 inhibited the [125l]azidoagosterol A‐photolabeling of P‐gp, but not that of MRP1. K562/MDR cells that overexpress P‐gp were 3.67 times more resistant to STI571 than the parental Philadelphia‐chromosome‐positive (Ph+) CML K562 cells, and this resistance was most effectively reversed by cepharanthine among the tested reversing agents. The concentration of STI571 required to completely inhibit tyrosine phosphorylation in K562/MDR cells was about 3 times higher than that in K562 cells, and cepharanthine abolished the difference. In KB‐G2 cells that overexpress P‐gp, but not Bcr‐Abl, 2.5 μM STI571 partly reversed the resistance to vincristine (VCR), paclitaxel, etoposide (VP‐16) and actinomycin D (ACD) but not to Adriamycin (ADM) or colchicine. STI571 increased the accumulation of VCR, but not that of ADM in KB‐G2 cells. STI571 did not reverse resistance to any agent in KB/MRP cells that overexpress MRP1. These findings suggest that STI571 is a substrate for P‐gp, but is less efficiently transported by P‐gp than VCR, and STI571 is not a substrate for MRP1. Among the tested reversing agents that interact with P‐gp, cepharanthine was the most effective agent for the reversal of the resistance to STI571 in K562/ MDR cells. Furthermore, STI571 itself was a potent reversing agent for MDR in P‐gp‐expressing KB‐G2 cells.

References

  • 1. Melo JV. The diversity of BCR‐ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375–84. [PubMed] [Google Scholar]
  • 2. Raitano AB, Whang YE, Sawyers CL. Signal transduction by wild‐type and leukemogenic Abl proteins. Biochim Biophys Acta 1997; 1333: F201–16. [DOI] [PubMed] [Google Scholar]
  • 3. Skorska NM, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T. Signal transducer and activator of transcription (STAT) 5 activation by BCR/ABL is dependent on intact Src homology (SH) 3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 1999; 189: 1229–42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR‐ABL‐positive cells. Blood 1997; 90: 3691–8. [PubMed] [Google Scholar]
  • 5. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV. Selection and characterization of BCR‐ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070–9. [PubMed] [Google Scholar]
  • 6. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385–427. [DOI] [PubMed] [Google Scholar]
  • 7. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug‐resistant human lung cancer cell line. Science 1992; 258: 1650–4. [DOI] [PubMed] [Google Scholar]
  • 8. Kuwazuru Y, Yoshimura A, Hanada S, Ichikawa M, Saito T, Uozumi K, Utsunomiya A, Arima T, Akiyama S. Expression of multidrug transuporter, P‐glycoprotein, in chronic myelogenous leukemia cells in blast crisis. Br J Haematol 1990; 74: 24–9. [DOI] [PubMed] [Google Scholar]
  • 9. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155–99. [PubMed] [Google Scholar]
  • 10. Sikic BI. Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993; 11: 1629–35. [DOI] [PubMed] [Google Scholar]
  • 11. Shiraishi N, Shimada T, Kobayashi M, Kuwano M, Akiyama S. Effect of biscoclaurine alkaloids on multidrug‐resistance in the KB human cancer cells. Cancer Res 1987; 47: 2413–6. [PubMed] [Google Scholar]
  • 12. Nagayama S, Chen Z‐S, Kitazono M, Takebayashi Y, Niwa K, Yamada K, Tani A, Haraguchi M, Sumizawa T, Furukawa T, Aikou T, Akiyama S. Increased sensitivity to vincristine of MDR cells by the leukotriene D4 receptor antagonist, ONO‐1078. Cancer Lett 1998; 130: 175–82. [DOI] [PubMed] [Google Scholar]
  • 13. Shudo N, Mizoguchi T, Kiyosue T, Arita M, Yoshimura A, Seto K, Sakoda R, Akiyama S. Two pyridine analogues with more effective activity to reverse multidrug resistance and lower calcium channel bloking activity than their dihydropyridine counterparts. Cancer Res 1990; 50: 3055–61. [PubMed] [Google Scholar]
  • 14. Baba M, Okamoto M, Kashiwada N, Ono M. Anti‐HIV‐1 activity and structure‐activity relationship of cepharanoline derivatives in chronically infected cells. Anti Chem. 2002; 12: 307–12. [DOI] [PubMed] [Google Scholar]
  • 15. Aoki S, Yoshioka Y, Miyamoto YKH, Setiawan A, Murakami N, Chen Z, Sumizawa T, Akiyama S, Kobayashi M. Agosterol A, a novel polyhydroxylated sterol acetate reversing multidrug resistance from a marine sponge of Spongia sp. Tetrahedron Lett 1998; 39: 6303–6. [Google Scholar]
  • 16. Ren XQ, Furukawa T, Aoki S, Nakajima T, Sumizawa T, Haraguchi M, Chen Z, Kobayashi M, Akiyama S. Glutathione‐dependent binding of a photoaffinity analog of agosterol A to the C‐terminal half of human multidrug resistance protein. J Biol Chem 2001; 276: 23197–206. [DOI] [PubMed] [Google Scholar]
  • 17. Ueda K, Shimabuku AM, Konishi H, Fujii Y, Takebe S, Nishi K, Yoshida M, Beppu T, Komano T. Functional expression of human P‐glycoprotein in Schizosacchawmyces pombe . FEBS Lett 1993; 330: 279–82. [DOI] [PubMed] [Google Scholar]
  • 18. Taguchi Y, Yoshida A, Takada Y, Komano T, Ueda K. Anti‐cancer drugs and glutathione stimulate vanadate‐induced trapping of nucleotide in multidrug resistance‐associated protein (MRP). FEBS Lett 1997; 401: 11–4. [DOI] [PubMed] [Google Scholar]
  • 19. Cornwell MM, Gottesman MM, Pastan IH. Increased vinblastine binding to membrane vesicles from multidrug‐resistant KB cells. J Biol Chem. 1986; 261:7921–8. [PubMed] [Google Scholar]
  • 20. Bradford MM. A rapid and sensitive method for the quantitation of micro‐gram quantities of protein utilizing the principle of protein‐dye binding. Anal Biochem. 1976; 72: 248–54. [DOI] [PubMed] [Google Scholar]
  • 21. Debenham PG, Kartner N, Siminovitch L, Riordan JR, Ling V. DNA‐mediated transfer of multiple drug resistance and plasma membrane glycoprotein expression. Mol Cell Biol 1982; 2: 881–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Nagayama S, Chen ZS, Kitazono M, Takebayashi Y, Niwa K, Yamada K, Tani A, Haraguchi M, Sumizawa T, Furukawa T, Aikou T, Akiyama S. Increased sensitivity to vincristine of MDR cells by the leukotriene D4 receptor antagonist, ONO‐1078. Cancer Lett 1998; 130: 175–82. [DOI] [PubMed] [Google Scholar]
  • 23. Okumura H, Chen ZS, Sakou M, Sumizawa T, Furukawa T, Komatsu M, Ikeda R, Suzuki H, Hirota K, Aikou T, Akiyama SI. Reversal of P‐glycoprotein and multidrug‐resistance protein‐mediated drug resistance in KB cells by 5‐O‐benzoylated taxinine K. Mol Pharmacol 2000; 58: 1563–9. [DOI] [PubMed] [Google Scholar]
  • 24. Ishikawa T. ATP/Mg2+‐dependent cardiac transport system for glutathione S‐conjugates. A study using rat heart sarcolemma vesicles. J Biol Chem. 1989; 264: 17343–8. [PubMed] [Google Scholar]
  • 25. Ishikawa T, Ali Osman F. Glutathione‐associated cis‐diamminedichloroplatinum(II) metabolism and ATP‐dependent efflux from leukemia cells. Molecular characterization of glutathione‐platinum complex and its biological significance. J Biol Chem. 1993; 268: 20116–25. [PubMed] [Google Scholar]
  • 26. Druker BJ, Sawyer CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capadeville R, Talpaz M. Activity of a specific inhibitor of the BCR‐ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lympoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–42. [DOI] [PubMed] [Google Scholar]
  • 27. Gorre ME, Mohammed M, Ellwood K, Hsu H, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI‐571 cancer therapy caused by BCR‐ABL gene mutation or amplification. Science 2001; 293: 876–80. [DOI] [PubMed] [Google Scholar]
  • 28. Hofmann WK, de Vos S, Elashoff D, Gschaidmeier H, Hoelzer D, Koeffler HP, Ottmann OG. Relation between resistance of Philadelphia‐chromosome‐positive acute lymphoblastic leukemia to the tyrosine kinase inhibitor STI 571 and gene‐expression profiles: a gene‐expression study. Lancet 2002; 359:481–6. [DOI] [PubMed] [Google Scholar]
  • 29. Marx J. Cancer research. Why some leukemia cells resist STI‐571. Science 2001; 292: 2231–3. [DOI] [PubMed] [Google Scholar]
  • 30. Dubrez L, Eymin B, Sordet O, Droin N, Turhan AG, Solary E. BCR‐ABL delays apoptosis upstream of procaspase‐3 activation. Blood 1998; 91: 2415–22. [PubMed] [Google Scholar]
  • 31. Wu J, Suzuki H, Zhou YW, Liu W, Yoshihara M, Kato M, Akhand AA, Hayakawa A, Takeuchi K, Hossain K, Kurosawa M, Nakashima I. Cepharantine activates caspase and induces apoptosis in Jurkat and K562 human leukemia cell lines. J Cell Biochem. 2001; 82: 200–14. [DOI] [PubMed] [Google Scholar]
  • 32. Vigneri P, Wang JY Induction of apoptosis in chronic myelogeous leukemia cells through nuclear entrapment of BCR‐ABL tyrosine kinase. Nat Med 2001; 7: 228–34. [DOI] [PubMed] [Google Scholar]
  • 33. Akiyama S, Yoshimura A, Kikuchi H, Sumizawa T, Kuwano M, Tahara Y. Synthetic isoprenoid photoaffinity labeling of P‐glycoprotein specific to multidrug‐resistant cells. Mol Pharmacol 1989; 36: 730–5. [PubMed] [Google Scholar]
  • 34. Damiani D, Michieli M, Michelutti A, Fanin R, Russo D, Baccarani M. P170 glycoprotein expression and impaired anthracycline retention in chronic myeloid leukaemia. Leak Lymphoma 1995; 17: 289–94. [DOI] [PubMed] [Google Scholar]
  • 35. Michelutti A, Michieli M, Damiani D, Melli C, Geromin A, Russo D, Fanin R, Baccarani M. Overexpression of MDR‐related p170 glycoprotein in chronic myeloid leukemia. Haem.atologica 1994; 79: 200–4. [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES